| Bioactivity | L18I is a Btk-targeting PROTAC that reduces inflammation in autoimmune diseases. L18I consists of PROTAC target protein ligand IBT6A (HY-13036A), PROTAC Linker Propargyl-PEG3-alcohol (HY-41921) and E3 ubiquitin ligase ligand Lenalidomide-Br (HY-43722), where the active control of the target protein ligand is IBT6A-CO-ethyne (HY-163963), and the conjugate of E3 ubiquitin ligase ligand + Linker is Lenalidomide-C3-PEG3-N3 (HY-163964)[1]. |
| Target | Btk |
| Formula | C47H51N11O8 |
| Molar Mass | 897.98 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |